Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (476)
Cancellation by sponsor (195)
Cancellation or suspension (77)
Prescription medicine registration (37)
Cancellation for failure to pay annual charge (17)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (4)
Prescription medicine evaluation (1)

Date

2024 (73)
2023 (102)
2022 (74)
2021 (76)
2020 (120)
2019 (22)
2018 (69)
2017 (106)
2016 (31)
2015 (36)
2014 (21)
2013 (9)
2012 (5)
2011 (6)
2010 (20)
2009 (5)
2008 (3)
2007 (6)
2006 (7)
2005 (2)
2004 (2)
2003 (4)
2002 (3)
2001 (4)
2000 (1)
1999 (2)
1998 (1)
1996 (1)

Results for "[search-keyword]"

Search

Sponsor content

811 result(s) found, displaying 231 to 240

Suspended from ARTG - RANITIDINE CA 300 ranitidine (as hydrochloride) 300 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
PHARMACY PLUS MUCUS RELIEF bromhexine hydrochloride 8mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
BICOF CHESTY bromhexine hydrochloride 1.6mg/mL oral liquid bottle Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - RANCIP 150 ranitidine (as hydrochloride) 150 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - RANITIDINE CA 150 ranitidine (as hydrochloride) 150 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - CIPLA RANITIDINE 150 ranitidine (as hydrochloride) 150 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
PHARMACY PLUS DOUBLE ACTION BROMHEXINE + GUAIFENESIN oral liquid bottle Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
PHARMACY SELECT CLOTRIMAZOLE 1% CREAM 10 mg/g tube Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
PHARMACOR CYPROTERONE 100 cyproterone acetate 100mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
PHARMACOR CYPROTERONE 50 cyproterone acetate 50mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd

Pages

First page
Previous page
…
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.